October 06, 2025

Dupilumab Shows High Treatment Persistence in AD

Biologics target type 2 inflammation in atopic dermatitis, improving skin barrier and symptoms.

Conexiant

October 02, 2025

Nicotinamide Use Reduces SCC in Veterans With Prior Skin Cancer

Veterans were prescribed nicotinamide twice daily following prior skin cancer.

Conexiant

October 01, 2025

How Safe Are FDA-Cleared AI Tools?

“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."

Conexiant

October 01, 2025

Remibrutinib Gains FDA Nod for Urticaria

First oral BTK inhibitor approved for antihistamine-resistant chronic spontaneous urticaria, targeting mast cell–driven immune dysregulation

Conexiant

September 30, 2025

Multiple Suits: Red Flag or Noise?

Cosmetic surgery chains expanded with emergency-licensed, out-of-state surgeons; lawsuits and disciplinary records challenge credentialing, “fellowship” claims, and patient protections in an industry without public complication tracking.

KFF Health News

September 26, 2025

Cutaneous Squamous Cell Carcinoma: AI Model Rivals Dermatologists in Differentiation Assessment

Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results o...

The ASCO Post

September 25, 2025

Utah Study Finds Fewer Melanoma Cases With Tattoos

Tattooed patients show varying melanoma risks by session number.

Conexiant

September 23, 2025

Juvenile SLE: Feasibility of Early Glucocorticoid Tapering

Early glucocorticoid tapering in juvenile systemic lupus erythematosus is feasible without added flare risk, though anti-double-stranded DNA positivity signals higher relapse odds.

Conexiant

September 19, 2025

New Topical JAK Inhibitor Option for Kids

The FDA approved ruxolitinib cream for children aged 2 to 11 with mild to moderate atopic dermatitis.

Conexiant